Fridge-Free Vaccines Could Reduce Global Vaccine Waste

A first-in-human clinical trial found a fridge-free tetanus-diphtheria vaccine generated immune responses comparable to the standard refrigerated vaccine after room-temperature storage.

One of the greatest challenges in global vaccination is not developing vaccines but ensuring they remain effective until they reach the people who need them. Most vaccines require continuous refrigeration throughout storage and transport, making immunization difficult in remote regions, disaster zones, and areas with unreliable electricity. Now, a first-in-human Phase 1 clinical trial suggests that a fridge-free tetanus-diphtheria vaccine (SPVX02), stored at room temperature for an extended period, can generate immune responses comparable to conventional refrigerated vaccines. If confirmed in larger studies, this technology could help reduce global vaccine waste, simplify vaccine distribution, and improve access to life-saving immunization worldwide.
The randomized, blinded, multicentre study enrolled 60 healthy adults and evaluated SPVX02, a room-temperature stabilized tetanus-diphtheria vaccine developed by Stablepharma. Instead of being stored as a liquid, the vaccine was preserved as a dry powder using a stabilization process before being reconstituted with sterile water immediately before administration. Researchers reported that the vaccine was safe, well tolerated, and produced immune responses comparable to those generated by licensed refrigerated tetanus-diphtheria vaccines.

Why Is Vaccine Refrigeration Still a Global Healthcare Challenge?

Most vaccines require strict temperature control throughout manufacturing, transportation, storage, and administration to maintain their effectiveness.

This uninterrupted temperature-controlled process, known as the cold chain, remains one of the biggest logistical challenges in global immunization programmes, particularly in low-resource settings, remote communities, humanitarian emergencies, and conflict-affected regions where reliable refrigeration and electricity may not always be available.

According to the World Health Organization (WHO), approximately half of all vaccines worldwide are wasted, with cold chain failures representing one of several important contributing factors, alongside transport damage, expired stock, and unused multidose vials.

How Does the Fridge-Free Vaccine Technology Work?

The technology uses the naturally occurring sugar trehalose, which helps protect biological structures during dehydration. Researchers combined this stabilizing approach with a specialized drying process that allows the vaccine to be stored as a powder rather than as a refrigerated liquid.

Immediately before administration, the dried vaccine is reconstituted with sterile water. This approach is designed to preserve the vaccine’s active biological components during long-term storage without continuous refrigeration.

According to the study, SPVX02 remained stable after storage at temperatures of up to 30°C for at least 18 months. Researchers also reported laboratory evidence suggesting stability after repeated temperature cycling between −20°C and +40°C, indicating that the formulation may tolerate variable transport conditions encountered during vaccine distribution.

What Did the First Human Trial of the Fridge-Free Vaccine Show?

Participants were randomly assigned to receive either SPVX02 or one of two licensed tetanus-diphtheria vaccines used as comparators.

The investigators found that the immune responses generated by the fridge-free vaccine were comparable to those produced by the licensed vaccines. The study also found the vaccine to be safe and well tolerated, with no serious safety concerns identified during the trial period.

The trial was designed to evaluate safety, tolerability, and immunogenicity, rather than protection against disease. Based on these findings, the researchers concluded that the results support continued clinical development of the room-temperature stabilized vaccine formulation.

The encouraging results from this early clinical trial support further evaluation of SPVX02 in larger studies. According to the researchers, the technology could help simplify vaccine distribution by reducing dependence on continuous refrigeration while maintaining vaccine quality during storage and transport.

Because the licensed tetanus-diphtheria vaccine has already been approved for use, the room-temperature stabilized formulation is being evaluated to demonstrate that it performs comparably while offering practical advantages for storage and distribution.

The researchers reported that SPVX02 remained stable for at least 18 months at temperatures up to 30°C. They also found laboratory evidence that the formulation tolerated repeated temperature cycling between −20°C and +40°C, suggesting that it may withstand challenging transportation conditions encountered during vaccine distribution.

The study further showed that the room-temperature stabilized vaccine generated immune responses comparable to licensed refrigerated vaccines while maintaining a favourable safety and tolerability profile throughout this Phase 1 clinical trial.

What Are the Next Steps for Fridge-Free Vaccine Research?

The researchers concluded that the positive findings support continued clinical development of SPVX02. Larger clinical studies are planned to further evaluate its safety, tolerability, and immunogenicity in a broader population.

If future studies confirm these findings, room-temperature vaccine stabilization could help reduce vaccine losses caused by temperature excursions while simplifying storage and transportation, particularly in areas where maintaining the cold chain remains difficult.

Although this technology is currently being evaluated using a tetanus-diphtheria vaccine, the stabilization platform may also be explored for other vaccines and biological medicines that require refrigerated storage. Additional research will determine how broadly this approach can be applied.

The findings have been published as a preprint on medRxiv and have not yet undergone peer review.

This first-in-human study marks an important step in the development of fridge-free vaccines. While additional clinical evaluation is still needed, the results demonstrate that room-temperature stabilization can preserve vaccine safety and immunogenicity without continuous refrigeration. If confirmed in future trials, this approach could help strengthen global immunization programmes by making vaccine storage and distribution more practical while reducing avoidable vaccine waste.

Reference:

1. Reed TAN, Clarke P, de la Torre Arrieta J, et al. Safety, tolerability and immunogenicity of SPVX02, a room temperature-stabilised Tetanus-Diphtheria vaccine compared to Tetadif and diTeBooster: a multicentre, phase 1, blinded, randomised clinical trial. (https://doi.org/10.64898/2026.03.09.26347956)

Source-medRxiv (Original Research)